Core Viewpoint - The Schall Law Firm is investigating Albany International Corp. for potential violations of securities laws related to misleading statements and undisclosed information affecting investors [1][2]. Group 1: Investigation Details - The investigation centers on whether Albany issued false or misleading statements and failed to disclose relevant information to investors [2]. - Albany reported Q2 2025 financial results on July 30, 2025, showing non-GAAP earnings per share that significantly missed consensus estimates [2]. - The President and CEO of Albany acknowledged that earnings "lagged our expectations," attributing this to "certain timing and operational issues" [2]. Group 2: Market Reaction - Following the disappointing earnings report, shares of Albany fell by more than 23.6% the next day [2].

Core Viewpoint - A class action lawsuit has been filed against Spectrum Pharmaceuticals, Inc. for alleged violations of securities laws, specifically related to misleading statements about the efficacy of its lung cancer treatment, poziotinib [1][2]. Group 1: Lawsuit Details - The class period for the lawsuit is from March 17, 2022, to September 22, 2022, with a deadline for lead plaintiff appointments set for September 24, 2025 [2]. - The complaint alleges that Spectrum made false and misleading statements regarding the results of its Pinnacle Study for poziotinib, which were less favorable than presented to investors [2]. Group 2: Shareholder Participation - Shareholders who purchased SPPI shares during the class period are encouraged to contact the law firm for potential lead plaintiff appointments, although this is not a requirement for recovery [2][3]. - Once registered, shareholders will be enrolled in a portfolio monitoring system to receive updates on the case's progress at no cost [3]. Group 3: Law Firm Background - DJS Law Group specializes in securities class actions and corporate governance litigation, focusing on enhancing investor returns through advocacy [4]. - The firm represents large hedge funds and alternative asset managers, emphasizing the value of litigation claims as significant assets [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Biohaven Ltd. regarding a class action lawsuit alleging that the company made materially false and misleading statements about its product candidates and their regulatory prospects [1][2]. Group 1: Allegations - The complaint claims that during the class period from March 24, 2023, to May 14, 2025, Biohaven overstated the regulatory prospects of its product candidate, troriluzole, as a treatment for SCA [1]. - It is alleged that the efficacy and clinical prospects of BHV-7000 for bipolar disorder were also overstated [1]. - The revelations of these overstated claims are likely to have a significant negative impact on Biohaven's business and financial condition [1]. Group 2: Class Action Details - Shareholders who purchased shares of BHVN during the specified class period are encouraged to register for the class action, with a deadline of September 12, 2025, to seek lead plaintiff status [2]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle [2]. - Participation in the case incurs no cost or obligation for the shareholders [2]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3].

Core Viewpoint - The Schall Law Firm is investigating Fortinet, Inc. for potential violations of securities laws, particularly regarding misleading statements and undisclosed information that may have affected investors [1][2]. Group 1: Investigation Details - The investigation centers on whether Fortinet issued false or misleading statements and failed to disclose critical information to investors [2]. - Fortinet's Q2 financial results, reported on August 6, 2025, have raised concerns among investors, particularly regarding the company's statement that 40% to 50% of its accelerated firewall refresh, estimated at $450 million and 650,000 units, was completed [2]. - Following the Q2 results and the confusion surrounding product revenue growth, Fortinet's shares dropped by 25.3% on August 7, 2025 [2].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of RxSight, Inc. regarding a class action lawsuit due to alleged misleading statements and undisclosed issues affecting the company's performance during a specified class period [1][2]. Summary by Relevant Sections Allegations - The complaint alleges that during the class period from November 7, 2024, to July 8, 2025, RxSight faced "adoption challenges" and structural issues leading to declines in sales and utilization [1]. - It is claimed that the defendants overstated the demand for RxSight's products [1]. - As a result of these issues, RxSight is unlikely to meet its previously issued financial guidance for fiscal year 2025 [1]. - The positive statements made by the defendants regarding the company's business and prospects were materially misleading and lacked a reasonable basis [1]. Class Action Details - Shareholders who purchased shares of RXST during the specified class period are encouraged to register for the class action, with a deadline of September 22, 2025, to seek lead plaintiff status [2]. - Registered shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle [2]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [3].

Core Viewpoint - The Gross Law Firm is notifying shareholders of Petco Health and Wellness Company, Inc. regarding a class action lawsuit related to misleading statements made by the company during the class period from January 14, 2021, to June 5, 2025 [3]. Group 1: Allegations Against Petco - Allegations include that Petco's pandemic-related growth was not sustainable and that its business model focused on premium pet food was overstated [3]. - The strength of Petco's differentiated product strategy was claimed to be exaggerated, and the company downplayed the severity of issues affecting its business [3]. - Defendants allegedly overstated Petco's ability to achieve sustainable, profitable growth, leading to materially false and misleading public statements [3]. Group 2: Class Action Details - The deadline for shareholders to register for the class action is August 29, 2025, and participation does not incur any cost or obligation [4]. - Shareholders who register will receive updates through a portfolio monitoring software regarding the status of the case [4]. - The Gross Law Firm aims to protect investors' rights and seeks recovery for losses incurred due to misleading statements by the company [5].

Core Viewpoint - Rowley Law PLLC is investigating potential securities law violations by HilleVax, Inc. related to its proposed acquisition by XOMA Royalty Corporation, where stockholders will receive $1.95 in cash and one contingent value right for each share held, with the transaction expected to close in September 2025 [1]. Group 1 - HilleVax, Inc. is under investigation for potential securities law violations concerning its acquisition by XOMA Royalty Corporation [1]. - Stockholders of HilleVax will receive $1.95 in cash and one contingent value right for each share they hold as part of the acquisition deal [1]. - The acquisition transaction is anticipated to close in September 2025 [1]. Group 2 - Rowley Law PLLC represents shareholders in class actions and derivative lawsuits in complex corporate litigation [3]. - Additional information regarding the investigation can be obtained by contacting Rowley Law PLLC [2].

BOSTON, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Block & Leviton LLP is investigating agilon health, Inc. (NYSE: AGL) for potential securities law violations. Investors who have lost money in their agilon investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/agl. Block & Leviton is investigating whether the Company committed securities law violations and may file an action to attempt to recover losses on behalf of investor ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Alto Neuroscience, Inc. regarding a class action lawsuit due to alleged misleading statements about the company's product pipeline and financial prospects [1][4]. Group 1: Class Action Details - The class action lawsuit is on behalf of all individuals and entities that purchased Alto common stock during the class period from February 2, 2024, to October 22, 2024 [3]. - Shareholders are encouraged to contact the Gross Law Firm for possible lead plaintiff appointment, although this is not required to participate in any recovery [1][5]. Group 2: Allegations - The complaint alleges that during the class period, the defendants made materially false and misleading statements regarding the effectiveness of the product ALTO-100 in treating major depressive disorder [4]. - It is claimed that the clinical, regulatory, and commercial prospects of ALTO-100 were overstated, leading to an inflated perception of Alto's business and financial prospects [4]. Group 3: Next Steps for Shareholders - Shareholders must register by September 19, 2025, to participate in the class action and will be enrolled in a portfolio monitoring software for updates on the case [5]. - There is no cost or obligation for shareholders to participate in the case [5]. Group 4: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered losses due to deceit and illegal business practices [6].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Vestis Corporation regarding a class action lawsuit due to allegations of misleading statements and failure to meet growth expectations [1][3]. Summary by Relevant Sections Allegations - The complaint alleges that Vestis Corporation provided overly positive statements while concealing material adverse facts about its business growth capabilities. Specifically, it was claimed that Vestis would struggle to execute strategic initiatives aimed at improving customer experience and driving new customer growth [3]. Financial Performance - On May 7, 2025, Vestis announced disappointing financial results for Q2 of fiscal 2025, withdrawing its revenue and growth guidance for the full fiscal year. The company reported a significant decline in stock price, dropping from $8.71 per share on May 6, 2025, to $5.44 per share on May 7, 2025, marking a decline of approximately 37.54% in one day [3]. Class Action Details - The class period for the lawsuit is defined as May 2, 2024, to May 6, 2025. Shareholders are encouraged to register for participation in the class action, with a deadline set for August 8, 2025. Registration allows shareholders to receive updates on the case [3][4]. Law Firm's Commitment - The Gross Law Firm emphasizes its mission to protect investors' rights against deceit and fraud, seeking recovery for those who suffered losses due to misleading statements that inflated stock prices [5].